Once-Daily Aptiom (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies
Dainippon Sumitomo Pharma Announces Revisions to Its Financial Forecasts for the Year Ended March 31, 2014
"Corporate profile" An English version and a Japanese version are updated.
Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression
Dainippon Sumitomo Pharma announces Changes in Executive Officers and Other Key Positions
Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
A Message from the President
Board of Directors and Executive Officers